【Abstract】Background and purpose :The survival of advanced gastric cancer Is poor, explore new second-line chemotherapy regimens is needed. Mehtods : 38 cases of the patients were treated weith Gemcitabine (1000 mg/m2) was given as a 30 min, infusion, adriamycin (50mg/m2),injection. The regimen was repeated every 3 weeks. Treatment efficacy was evaluated every 2 cycles. Results: Patients received a total of 132 cycles of treatment, and all were evaluable for effi cacy and toxicity. The response rate (RR) was 39.4%. The disease control rate (DCR) was 63.2%. The median survival time was 11.5 months. The survival rate was 35.7% in the first year. Conclusion:Gemcitabine combined with adriamycin regimen is effective in the treatment of advanced gastric cancer as second line treatment. The side-effects are mild. |